GLP-1 and Muscle Loss: The New Drugs Built to Protect Lean Mass, and What to Do Before They Arrive
Updated: 6 days ago
For two years the headline on GLP-1 medication has been the number on the scale. For a man over 40, the more useful number is how much of that weight was muscle. In the trials that measured it properly, the answer for tirzepatide on its own was close to a third.
Two drug programmes reported over the past eighteen months are aimed squarely at that problem. Neither is available for weight loss, and neither may be for some time. But they say a great deal about where obesity medicine is heading, and about what any man on a GLP-1 should be measuring now.
The Problem the New Drugs Are Trying to Solve
GLP-1 medicines work by reducing appetite, and a sustained calorie deficit costs lean tissue as well as fat. In the EMBRAZE trial, reported by Scholar Rock in June 2025, around 30 per cent of the weight lost by people taking tirzepatide alone over 24 weeks was lean mass, measured on DEXA. Across the wider literature the figure runs from roughly a quarter to two fifths, depending on the drug, the dose and the person. We set out the practical side of this in our article on oral GLP-1 and what it means for your muscle.
For a younger patient that loss may matter little. For a man in his forties or fifties, already losing muscle with age, treatment opens what we call the lean mass window: the months in which lean tissue is most at risk, and the part of GLP-1 treatment least likely to be measured.
Apitegromab: Releasing the Brake on Muscle
Myostatin is a protein the body uses to limit muscle growth. Apitegromab is an antibody that blocks its activation, originally developed for spinal muscular atrophy. In EMBRAZE, around 100 adults living with overweight or obesity took tirzepatide alongside either apitegromab or a placebo, given by infusion every four weeks.
After 24 weeks, total weight loss was similar: 12.3 per cent with the combination and 13.4 per cent with tirzepatide alone. What changed was its composition. With apitegromab, lean mass made up around 15 per cent of the weight lost, against 30 per cent on tirzepatide alone, which meant roughly 1.9 kg more lean tissue kept.
Bimagrumab: A Larger and Longer Trial
The BELIEVE trial, published in Nature Medicine in March 2026, tested bimagrumab, an antibody that blocks a related set of signals known as the activin pathways, alongside semaglutide over 72 weeks.
Semaglutide alone produced an average weight loss of 15.7 per cent, with about 72 per cent of it coming from fat. The combination produced 22.1 per cent, with about 93 per cent from fat and lean mass largely preserved. On its own, bimagrumab produced weight loss that came entirely from fat, while lean mass rose slightly.

What These Trials Do Not Tell You Yet
Both are phase 2 trials, both were funded by the companies developing the drugs, and both measured lean mass rather than strength or physical function. EMBRAZE ran for 24 weeks. Acne and muscle spasms were noted in the bimagrumab groups, and larger, longer trials are needed before either drug reaches routine practice. Neither is approved for weight management.
Lean mass is also not quite the same thing as muscle. DEXA counts everything that is neither fat nor bone, including water and organ tissue, so some of the lean mass lost on a GLP-1 is not skeletal muscle at all. That cuts both ways: the problem may be a little smaller than the headline figures suggest, and so may the benefit of the new drugs.
The Bigger Signal: Body Composition Is Now the Endpoint
The most important thing about these trials may be what they chose to measure. Both judged success on the composition of the weight lost, not the amount, and the BELIEVE study itself points to the need to move obesity care beyond weight and BMI towards body composition.
That has been the Miller Health position from the start. Weight is an outcome. Body composition is the measurement.
What to Do While You Wait
Measure before you start
A DEXA scan before treatment gives a baseline for lean mass, fat distribution and bone density. Without one, there is no way of knowing later what the medication has cost you.
Protect the muscle you have
Progressive resistance training two or three times a week, and enough protein spread across the day, remain the best-supported ways to hold on to lean mass during weight loss. Appetite suppression makes the protein harder, not easier, which is why it needs a plan rather than good intentions. Our article on why muscle is the metric that predicts your next two decades explains why this matters beyond the treatment itself.
Re-measure during treatment
A repeat scan part way through treatment shows whether the plan is working while there is still time to change it. Bone density deserves the same attention, as we explain in GLP-1 weight loss and your skeleton.
Frequently Asked Questions
Can I get apitegromab or bimagrumab now?
Not for weight loss. Both remain investigational in this use and are available only within clinical trials.
How much muscle will I lose on a GLP-1?
It varies widely. Trial averages suggest that somewhere between a quarter and two fifths of the weight lost comes from lean mass, and the individual figure depends on age, training, protein intake and how fast the weight comes off. The only way to know yours is to measure it.
Should I avoid GLP-1 medication because of this?
No. For many men the metabolic benefits are substantial. The point is to use it with your body composition measured, so that the weight you lose is mostly the weight you wanted to lose.
Start With the Measurement
The Explore assessment is £1,950 and takes place at 25 Harley Street, London: a DEXA scan and an advanced blood and hormone panel, interpreted together by an HCPC-registered dietitian, with a personalised feedback consultation. For men already taking a GLP-1, our article on the dietitian's role on GLP-1 medication explains how the protein and training plan is built around those results. Book at millerhealth.london.
Where do you stand?
Take the 3-minute Miller Health Score: four areas, plain-English results, and our guide to the 12 measures every man over 40 should understand.



Comments